 |
 |
|
|
|||||
|
OAB affects approximately 16% of the population, and its prevalence is similar for both men and women: 16.0% for men and 16.9% for women. However, more women than men experience what many consider to be the most troublesome symptom, urge incontinence. Whether or not an individual experiences urge incontinence along with other symptoms such as urgency and frequency, OAB is likely to have a negative impact on quality of life, mental health, and quality of sleep.4 The prevalence of OAB increases with advancing age in both men and women, approaching 30% for men and women aged 65 to 74.4 Despite the prevalence of the syndrome, OAB is underdiagnosed and undertreated. 40% of patients who suffer from OAB do not discuss their symptoms with their doctors. The most common reason given for the failure to consult a physician is the belief that no effective treatment is available.3 In addition, some of your patients may consider OAB an inevitable aspect of aging and fail to seek treatment.5 Because many patients may be reluctant to talk about their symptoms with their doctors, you should consider asking your patients about OAB symptoms during physical examinations. |
| vesicarerx.com |
| Learn more about VESIcare with an interactive online experience. Click here. |
| Patient Resources |
| VESIcare can help you and your patients address overactive bladder together. The Fresh Approach Kit includes a bladder checklist, a bladder diary, and a list of questions for patients to ask physicians. Download Fresh Approach Kit. The Vantage ProgramSM provides valuable information and exclusive savings for your patients. Click here to learn more. |
| Important Safety Information VESIcare tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. The recommended dose of VESIcare is 5 mg once daily. If the 5-mg dose is well tolerated, the dose may be increased to 10 mg once daily. As with other anticholinergic agents, VESIcare is contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and in patients with hypersensitivity to the product. As with other anticholinergic agents, VESIcare should be administered with caution to patients with bladder outflow obstruction, decreased gastrointestinal motility, controlled narrow-angle glaucoma, or reduced renal or hepatic function. Doses of VESIcare higher than 5 mg are not recommended in patients with severe renal impairment, moderate hepatic impairment, or when administered with ketoconazole or other potent CYP3A4 inhibitors. Use of VESIcare in patients with severe hepatic impairment is not recommended. In placebo-controlled studies, the most common adverse events reported by patients were dry mouth (10.9%, 27.6%, 4.2%), constipation (5.4%, 13.4%, 2.9%), blurred vision (3.8%, 4.8%, 1.8%), and dyspepsia (1.4%, 3.9%, 1.0%) with VESIcare 5 mg, 10 mg, and placebo, respectively. The overall rate of serious adverse events was 2%. For the 10-mg dose, three intestinal serious adverse events were reported (one fecal impaction, one colonic obstruction, and one intestinal obstruction). For the 5-mg dose, one case of angioneurotic edema was reported. |
|
Complete Prescribing Information for VESIcare |
|
|
VESIcare is a registered trademark of Astellas Pharma Inc. This site is intended for US residents only. © 2005-2007 Astellas Pharma US, Inc. and The GlaxoSmithKline Group of Companies All rights reserved. |
| Legal Notices | Privacy Statement | Contact Us | Site Map |